SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is actively trending as the community leans into its legacy as a 15-year-old parody of Bitcoin, with investors debating its long-term potential compared to serious financial assets. Discussion is largely fueled by the project's historical roots and a growing community narrative that frames the meme as an inevitable fixture in the crypto space.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is drawing intense scrutiny as investors weigh its mixed earnings and cautious outlook against a backdrop of fierce EV competition and a recent recall involving battery safety. The community remains deeply polarized, with some traders betting on a turnaround fueled by the launch of the i6 and i8 models, while others are aggressively shorting the stock, pointing to slowing sales momentum and aggressive rivalry from competitors like Nio.

Maulcoin

Maulcoin is trending as investors rally behind a community-driven, organic growth strategy, actively pushing for a breakout while anticipating airdrops and chart visibility. The community is heavily focused on holding through volatility and maintaining strong diamond hands to drive the token toward higher market capitalization milestones.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently at the center of a high-stakes debate between those reacting to political support and those skeptical of its valuation amid competition from Anthropic. The community is actively debating the significance of a high-profile endorsement of the stock's defense capabilities, while bears emphasize concerns over technical indicators and the potential impact of new AI model developments on the company's long-term competitive moat.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus is attracting investor interest as a high-performance memory play, with the community highlighting its strategic role in DDR5 and CXL technologies amid ongoing data center demand. While participants debate the impact of recent supply chain issues and executive turnover, many remain bullish, viewing the company as an undervalued infrastructure provider that is well-positioned for future memory bandwidth shifts.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is gaining momentum as investors connect the stock to Alphabet's acquisition of Intersect Power, a primary customer that relies on the company's domestic utility-scale solar modules to power growing AI data center energy demands. The broader market sentiment is reacting positively to this integration, fueling community discussion around First Solar's role as a critical energy provider for large-scale technology infrastructure.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is currently capturing investor attention as traders debate whether its recent volatility and price compression create a prime entry point ahead of upcoming earnings. While some investors are concerned by consistent selling pressure and the stock's struggle to reclaim key resistance levels, others are highlighting the company's improved profitability, strong cash flow, and potential for an acquisition as catalysts that could drive a sharp recovery.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is currently the subject of intense buyout speculation, fueled by the recent FDA grant of a landmark formal evidentiary hearing for its jet lag treatment and the approval of its bipolar medication, Bysanti. While investors are actively debating the impact of management's confrontational FDA strategy and price suppression, the community is closely monitoring the stock for potential acquisition by major pharmaceutical players looking to secure its high-value pipeline.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

The Vanguard Total Stock Market ETF is trending as investors debate the merit of broad market indexing versus tactical rotation strategies amid ongoing economic volatility and sector-specific concerns. Community discussions focus on the benefits of long-term capital accumulation through ETFs like VTI as a resilient hedge against market noise and speculative trading.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending as investors weigh significant balance sheet improvements, including a recent debt-to-equity conversion by leadership, against concerns over potential future dilution to fund rapid manufacturing expansion. The community is actively debating the company's long-term potential as a critical supplier for defense and aerospace giants like Anduril and SpaceX, while closely monitoring the upcoming earnings report for clarity on revenue growth and profitability timelines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Rating of "Hold" from Brokerages

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) have earned a consensus rating of "Hold" from the fourteen research firms that are covering the stock, Marketbeat Ratings...

Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?

Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders? Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 9, 2026 Insiders may stand to...

Promising Pharmaceutical Stocks To Add to Your Watchlist - April 9th

Eli Lilly and Company, Terns Pharmaceuticals, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies engaged in the discovery, development, manufacturing, and sale of prescription drugs and related...

AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?

Though both dominate oncology, a stronger growth outlook and clearer targets may give AstraZeneca an edge over Merck.

Why Terns Pharmaceuticals Stock Rocked the Market in March

Key PointsAll told, the transaction is valued at around $6.7 billion...

Best Pharmaceutical Stocks To Consider - April 8th

Eli Lilly and Company, Terns Pharmaceuticals, Soleno Therapeutics, Pfizer, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and market presc...

Value Stocks To Add to Your Watchlist - April 7th

Invesco QQQ, Sandisk, Intel, ProShares UltraPro Short QQQ, and Terns Pharmaceuticals are the five Value stocks to watch today, according to MarketBeat's stock screener tool. Value stocks are shares...

Top Mid Cap Stocks To Add to Your Watchlist - April 7th

ProShares UltraPro Short QQQ, Terns Pharmaceuticals, Direxion Daily TSLA Bull 2X Shares, Avis Budget Group, Applied Optoelectronics, Booking, and Soleno Therapeutics are the seven Mid Cap stocks to...

Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review

Merck cuts Terns deal price after TERN-701 data review, while maintaining interest amid competition and CML treatment comparisons.read more...

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

TERN
Terns Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TERN News

TERNTerns Pharmaceuticals Inc